Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac)
Por:
Mendez, R, Aldas, I and Menendez, R
Publicada:
1 feb 2020
Ahead of Print:
18 feb 2020
Resumen:
Community-acquired pneumonia (CAP) remains the first cause of morbidity and mortality worldwide due to infection. Several aspects such as severity and host response are related to its clinical course and outcome. Beyond the acute implications that the infection provokes in the host, pneumonia also has long-term negative consequences. Among them, cardiovascular complications and mortality are the most outstanding. Therefore, an adequate recognition and stratification of the risk of complications and mortality is crucial. Many biomarkers have been studied for these reasons, considering that each biomarker mirrors a different aspect. Moreover, the clinical application of many of them is still being deliberated because of their limitations and the heterogeneity of the disease. In this review, we examine some of the most relevant biomarkers that we have classified as cardiac and non-cardiac. We discuss some classic biomarkers and others that are considered novel biomarkers, which are mainly involved in cardiovascular risk.
Filiaciones:
Mendez, R:
Hosp Univ & Politecn La Fe, Inst Invest Sanitaria IIS La Fe, Pneumol Dept, Valencia 46026, Spain
Hosp Univ & Politecn La Fe, Pneumol Dept, Avda Fernando Abril Martorell 106, Valencia 46026, Spain
:
Univ Valencia, Med Fac, Valencia 46026, Spain
Hosp Badalona Germans Trias & Pujol, Pneumol Dept, Badalona 08916, Spain
Menendez, R:
Hosp Univ & Politecn La Fe, Inst Invest Sanitaria IIS La Fe, Pneumol Dept, Valencia 46026, Spain
Hosp Univ & Politecn La Fe, Pneumol Dept, Avda Fernando Abril Martorell 106, Valencia 46026, Spain
Univ Valencia, Med Fac, Valencia 46026, Spain
Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid 28029, Spain
Green Published, gold
|